We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Barr Laboratories and Teva Pharmaceuticals are facing a patent infringement lawsuit after filing ANDAs to market generic 30-, 60- and 90-mg strengths of Sensipar tablets, a treatment for secondary hyperparathyroidism in dialysis patients with chronic kidney disease.